GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.1 at the end of 2023 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...

With a rich background in brand positioning, Laura brings a wealth of strategic experience partnering with renowned organizations including Keurig Dr Pepper, Nestle, American Cancer Society, Merck, ...

Petrelli has experience in the Canadian biotech industry with a background in supporting people development, and leading ...

Brings Strong Background in Pharmaceutical Manufacturing Operations and Finance to Help Drive Performance and ProductivityJackie Klecker Named ...

ELIQUENT Life Sciences (ELIQUENT), a global regulatory consulting firm, today announced the appointment of Rob Wojciechowski ...

Gender equality is incomplete without gender health equality. Femtech can bridge the health equity gap in India by offering ...

GSK, MSD, Liberty Medical, Indivior and Galderma . He has worked with many teams to drive superior results in primary care, hospital, specialty, OTC, and devices. With a background in human ...

Recent graduates from UCL Biochemical Engineering have taken exciting roles at companies such as Merck, GSK, Pall, Oxford Biomedica ... In addition, students will be expected to work as teams on case ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...

Full Year 2024 Guidance: 7% to 9% sales growth, 11% to 13% profit growth. GSK PLC (NYSE:GSK) reported a 9% sales growth and 19% profit growth year-to-date, reflecting strong performance in ...